Phylogeny  
• Orthologs confirmed: Mus musculus Map3k2; knockout mice are viable and retain conserved kinase function (ahmad2018discoveryandcharacterization pages 1-6).  
• Closest paralog: MAP3K3 (MEKK3); high catalytic-domain identity and shared inhibitor susceptibility (ahmad2018discoveryandcharacterization pages 10-15).  
• Kinome placement: Member of the MAPK kinase kinase (MAP3K) family, MEKK/STE11 subfamily (zhang2006identificationofmekk23 pages 1-2).  

Reaction Catalyzed  
ATP + MAP2K5/7 (unphosphorylated) ⇌ ADP + MAP2K5/7-P (phosphorylated on Ser/Thr in the activation loop) (ahmad2018discoveryandcharacterization pages 1-6).  

Cofactor Requirements  
No specific divalent-cation requirement has been reported in the cited biochemical studies (ahmad2018discoveryandcharacterization pages 1-6, zhang2006identificationofmekk23 pages 1-2).  

Substrate Specificity  
• Direct substrates: MAP2K5 (MEK5) (cargnello2011activationandfunction pages 6-8), MAP2K7 (MEK7) (ahmad2018discoveryandcharacterization pages 1-6), MAP2K4 (MKK4) (hammaker2004regulationofcjun pages 6-7), and c-Jun (hammaker2004regulationofcjun pages 1-2).  
• A consensus phosphorylation motif has not been experimentally defined; docking interactions typical of MAP3Ks appear to dictate specificity (cargnello2011activationandfunction pages 6-8).  

Structure  
• Domain organization: N-terminal regulatory segment followed by a C-terminal Ser/Thr kinase domain (zhang2006identificationofmekk23 pages 10-11).  
• Activation segment: Ser519 (human numbering) within the activation loop is the principal regulatory phosphosite required for catalytic activity (zhang2006identificationofmekk23 pages 2-3).  
• Oligomeric state: Catalytic-domain dimerization is necessary for activation (zhang2006identificationofmekk23 pages 10-11).  
• Structural coverage: No crystallographic structures reported; biochemical assays employed recombinant catalytic domains for inhibitor profiling (ahmad2018discoveryandcharacterization pages 10-15).  

Regulation  
• Autophosphorylation: Ser519 phosphorylation is essential for kinase activation (zhang2006identificationofmekk23 pages 2-3).  
• Cytokine signaling: IL-1 markedly increases MEKK2 activity toward MKK4/MKK7 in fibroblast-like synoviocytes (hammaker2004regulationofcjun pages 6-7).  
• TLR/stress input: TRAF6-dependent phosphorylation at Ser519 following Toll-like receptor engagement (zhang2006identificationofmekk23 pages 1-2).  
• Ubiquitination: XIAP and cIAP1 catalyze ubiquitin attachment, modulating the MEKK2/3-MEK5-ERK5 module (takeda2014ubiquitin‐dependentregulationof pages 18-18).  
• Lysine methylation: SMYD3 methylates MEKK2, enhancing kinase activity in Ras-driven carcinoma models (nguyen2022map3kfamilyreview pages 2-3).  
• Allosteric control: Homodimerization of the catalytic domain is required for full activation (zhang2006identificationofmekk23 pages 10-11).  

Function  
• Expression: Elevated in prostate, breast, colorectal, gastric, lung, hepatocellular and triple-negative breast cancers (ahmad2018discoveryandcharacterization pages 1-6, nguyen2022map3kfamilyreview pages 2-3); highly expressed in rheumatoid-arthritis synovial tissue/fibroblast-like synoviocytes (hammaker2004regulationofcjun pages 1-2).  
• Upstream regulators: WNK1 kinase (cargnello2011activationandfunction pages 6-8), IL-1 receptor signaling (hammaker2004regulationofcjun pages 6-7), Toll-like receptors via TRAF6 (zhang2006identificationofmekk23 pages 1-2), Rac1/2 GTPases (takeda2014ubiquitin‐dependentregulationof pages 18-18).  
• Downstream pathways:  
  – MEK5 → ERK5 cascade controlling proliferation, survival and migration (cargnello2011activationandfunction pages 6-8, ahmad2018discoveryandcharacterization pages 1-6).  
  – MEK7/MKK4 → JNK → c-Jun axis driving AP-1 and matrix metalloproteinase expression (hammaker2004regulationofcjun pages 1-2, hammaker2004regulationofcjun pages 6-7).  
  – Contributes to IKK–NF-κB activation (zhang2006identificationofmekk23 pages 1-2).  
• Cellular roles: Regulates focal-adhesion turnover; knock-down stabilizes adhesions and suppresses cell migration (ahmad2018discoveryandcharacterization pages 1-6).  
• Physiological roles: Supports IL-2 production in T cells (zhang2006identificationofmekk23 pages 10-11); drives matrix-degrading enzyme expression in rheumatoid arthritis synoviocytes (hammaker2004regulationofcjun pages 1-2).  
• Genetic evidence: Mekk2-null mice are viable, indicating non-essentiality for embryogenesis (ahmad2018discoveryandcharacterization pages 1-6).  

Inhibitors  
• Iminocoumarin scaffold: Lead compound IC50 = 8 nM (biochemical); CF3 substitution confers high selectivity (ahmad2018discoveryandcharacterization pages 10-15).  
• Compound 1s: Cellular IC50 ≈ 60 nM for blockade of MEKK2-dependent ERK5 phosphorylation; cross-reactive with MEKK3 (ahmad2018discoveryandcharacterization pages 10-15).  
• Ponatinib: Multi-kinase inhibitor that also targets MEKK2 with limited selectivity (ahmad2018discoveryandcharacterization pages 1-6).  

Other Comments  
• Knock-down or pharmacological inhibition of MEKK2 reduces tumor growth and metastasis in vivo (ahmad2018discoveryandcharacterization pages 1-6).  
• Elevated MAP3K2 mRNA correlates with poor survival across multiple cancer types (nguyen2022map3kfamilyreview pages 2-3).  
• MEKK2 activity drives epithelial-mesenchymal transition and invasion in solid tumors (nguyen2022map3kfamilyreview pages 2-3).  
• MEKK2 is a key inflammatory mediator in rheumatoid arthritis, making it a potential therapeutic target for joint preservation (hammaker2004regulationofcjun pages 1-2).

References

1. (ahmad2018discoveryandcharacterization pages 1-6): Syed Ahmad, Valentine R. St. Hilaire, Srinivasa R. Dandepally, Gary L. Johnson, Alfred L. Williams, and John E. Scott. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of mekk2 (map3k2). Biochemical and biophysical research communications, 496 1:205-211, Jan 2018. URL: https://doi.org/10.1016/j.bbrc.2018.01.027, doi:10.1016/j.bbrc.2018.01.027. This article has 9 citations and is from a peer-reviewed journal.

2. (ahmad2018discoveryandcharacterization pages 10-15): Syed Ahmad, Valentine R. St. Hilaire, Srinivasa R. Dandepally, Gary L. Johnson, Alfred L. Williams, and John E. Scott. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of mekk2 (map3k2). Biochemical and biophysical research communications, 496 1:205-211, Jan 2018. URL: https://doi.org/10.1016/j.bbrc.2018.01.027, doi:10.1016/j.bbrc.2018.01.027. This article has 9 citations and is from a peer-reviewed journal.

3. (cargnello2011activationandfunction pages 6-8): Marie Cargnello and Philippe P. Roux. Activation and function of the mapks and their substrates, the mapk-activated protein kinases. Microbiology and Molecular Biology Reviews, 75:50-83, Mar 2011. URL: https://doi.org/10.1128/mmbr.00031-10, doi:10.1128/mmbr.00031-10. This article has 4045 citations and is from a domain leading peer-reviewed journal.

4. (hammaker2004regulationofcjun pages 1-2): D. Hammaker, D. Boyle, M. Chabaud-Riou, and G. Firestein. Regulation of c-jun n-terminal kinase by mekk-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis1. The Journal of Immunology, 172:1612-1618, Feb 2004. URL: https://doi.org/10.4049/jimmunol.172.3.1612, doi:10.4049/jimmunol.172.3.1612. This article has 110 citations.

5. (hammaker2004regulationofcjun pages 6-7): D. Hammaker, D. Boyle, M. Chabaud-Riou, and G. Firestein. Regulation of c-jun n-terminal kinase by mekk-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis1. The Journal of Immunology, 172:1612-1618, Feb 2004. URL: https://doi.org/10.4049/jimmunol.172.3.1612, doi:10.4049/jimmunol.172.3.1612. This article has 110 citations.

6. (nguyen2022map3kfamilyreview pages 2-3): Khoa Nguyen, Minh N. Tran, Andrew Rivera, Thomas Cheng, Gabrielle O. Windsor, Abraham B. Chabot, Jane E. Cavanaugh, Bridgette M. Collins-Burow, Sean B. Lee, David H. Drewry, Patrick T. Flaherty, and Matthew E. Burow. Map3k family review and correlations with patient survival outcomes in various cancer types. Frontiers in Bioscience-Landmark, 27:167, May 2022. URL: https://doi.org/10.31083/j.fbl2705167, doi:10.31083/j.fbl2705167. This article has 24 citations.

7. (takeda2014ubiquitin‐dependentregulationof pages 18-18): Armelle‐Natsuo Takeda, Tripat Kaur Oberoi‐Khanuja, Gabor Glatz, Katharina Schulenburg, Rolf‐Peter Scholz, Alejandro Carpy, Boris Macek, Attila Remenyi, and Krishnaraj Rajalingam. Ubiquitin‐dependent regulation of mekk2/3‐mek5‐erk5 signaling module by xiap and ciap1. The EMBO Journal, 33:1784-1801, Aug 2014. URL: https://doi.org/10.15252/embj.201487808, doi:10.15252/embj.201487808. This article has 34 citations.

8. (zhang2006identificationofmekk23 pages 1-2): Dongyu Zhang, Valeria Facchinetti, Xiaofang Wang, Qiaojia Huang, Jun Qin, and Bing Su. Identification of mekk2/3 serine phosphorylation site targeted by the toll‐like receptor and stress pathways. The EMBO Journal, Jan 2006. URL: https://doi.org/10.1038/sj.emboj.7600913, doi:10.1038/sj.emboj.7600913. This article has 71 citations.

9. (zhang2006identificationofmekk23 pages 2-3): Dongyu Zhang, Valeria Facchinetti, Xiaofang Wang, Qiaojia Huang, Jun Qin, and Bing Su. Identification of mekk2/3 serine phosphorylation site targeted by the toll‐like receptor and stress pathways. The EMBO Journal, Jan 2006. URL: https://doi.org/10.1038/sj.emboj.7600913, doi:10.1038/sj.emboj.7600913. This article has 71 citations.

10. (zhang2006identificationofmekk23 pages 10-11): Dongyu Zhang, Valeria Facchinetti, Xiaofang Wang, Qiaojia Huang, Jun Qin, and Bing Su. Identification of mekk2/3 serine phosphorylation site targeted by the toll‐like receptor and stress pathways. The EMBO Journal, Jan 2006. URL: https://doi.org/10.1038/sj.emboj.7600913, doi:10.1038/sj.emboj.7600913. This article has 71 citations.
